Immunic Secures $200 Million Financing to Advance Multiple Sclerosis Research
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy IMUX?
Source: Newsfilter
- Successful Financing: Immunic has successfully completed an oversubscribed private placement of up to $400 million, with $200 million in initial gross proceeds, which is expected to fund its multiple sclerosis (MS) projects and facilitate the company's transition to a commercial-stage organization.
- Clinical Trial Progress: Top-line data from the ENSURE-1 and ENSURE-2 Phase 3 trials for multiple sclerosis is anticipated by the end of 2026, laying the groundwork for future drug applications and market launches, with potential regulatory approval expected in 2028.
- New Drug Application Plans: The company plans to submit a New Drug Application (NDA) in mid-2027 for vidofludimus calcium in the U.S. market, which is expected to significantly enhance its competitiveness in the projected $30 billion global multiple sclerosis market.
- Board Changes: Immunic has appointed a new interim chairperson of the board and initiated a search for a new CEO with commercial expertise to support the company's further development in the multiple sclerosis field.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMUX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMUX
Wall Street analysts forecast IMUX stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.948
Low
3.00
Averages
4.25
High
8.00
Current: 0.948
Low
3.00
Averages
4.25
High
8.00
About IMUX
Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Immunic Reports FY 2025 Earnings with Positive Cash Outlook
- Earnings Highlights: Immunic reported a FY 2025 GAAP EPS of -$0.62, beating expectations by $0.05, indicating improvements in financial management despite ongoing losses.
- Cash Position: As of December 31, 2025, Immunic had approximately $15.5 million in cash and cash equivalents, providing a short-term liquidity buffer that ensures operational stability in the coming months.
- Funding Strategy: The company raised approximately $187 million in net cash from a private placement in February 2026, enabling it to fund operations into late 2027, which bolsters market confidence in its sustainability.
- Market Reaction: Following the announcement of a $400 million private placement, Immunic's stock price rose, reflecting investor optimism about the company's future, particularly in light of leadership transitions.
See More
Immunic Secures $200 Million Financing to Advance Multiple Sclerosis Research
- Successful Financing: Immunic has successfully completed an oversubscribed private placement of up to $400 million, with $200 million in initial gross proceeds, which is expected to fund its multiple sclerosis (MS) projects and facilitate the company's transition to a commercial-stage organization.
- Clinical Trial Progress: Top-line data from the ENSURE-1 and ENSURE-2 Phase 3 trials for multiple sclerosis is anticipated by the end of 2026, laying the groundwork for future drug applications and market launches, with potential regulatory approval expected in 2028.
- New Drug Application Plans: The company plans to submit a New Drug Application (NDA) in mid-2027 for vidofludimus calcium in the U.S. market, which is expected to significantly enhance its competitiveness in the projected $30 billion global multiple sclerosis market.
- Board Changes: Immunic has appointed a new interim chairperson of the board and initiated a search for a new CEO with commercial expertise to support the company's further development in the multiple sclerosis field.
See More
Immunic Secures $400 Million for MS Trials and Transition
- Successful Financing: Immunic has successfully completed an oversubscribed private placement of up to $400 million, with $200 million in upfront gross proceeds, which positions the company for a confident transition into a fully integrated commercial-stage entity, reflecting investor confidence in its multiple sclerosis (MS) treatment program.
- Clinical Trial Progress: The phase 3 ENSURE trials for Immunic's lead asset, vidofludimus calcium (IMU-838), in relapsing multiple sclerosis (RMS) are expected to yield top-line data by the end of 2026, providing critical insights for future drug applications and market entry.
- New Drug Application Plans: The company plans to submit a New Drug Application (NDA) for RMS in the U.S. by mid-2027, with a targeted regulatory approval date in 2028, which will prepare for the potential launch of vidofludimus calcium and enhance its competitive position in the global MS market projected to exceed $30 billion.
- Innovative Mechanism of Action: Vidofludimus calcium, as a first-in-class Nurr1 activator, aims to improve neuronal survival and function through direct neuroprotective effects and selective DHODH inhibition, potentially offering a best-in-class benefit-risk profile that could unlock significant commercial opportunities in MS treatment.
See More
Immunic Inc. Stock Soars on Oversubscribed Private Placement Announcement
- Funding Initiative: Immunic Inc. announced an oversubscribed private placement aimed at raising up to $400 million to accelerate its transformation into a commercial-stage company, which is expected to significantly enhance its market competitiveness.
- Equity Financing Details: The company will issue 229.08 million pre-funded warrants at $0.873 each, with expected upfront gross proceeds of $200 million, and will also issue warrants to purchase up to 229.076 million shares, potentially raising an additional $200 million.
- Clinical Trial Support: The funding is intended to support the completion of the Phase 3 ENSURE trial for relapsing multiple sclerosis, with topline data expected by the end of 2026, and plans to submit a New Drug Application in mid-2027, targeting regulatory approval in 2028.
- Leadership Changes: Immunic has made significant leadership changes by appointing Simona Skerjanec as interim Chairperson of the Board and initiating a search for a new CEO with commercial expertise, indicating a major strategic shift within the company.
See More
Immunic Inc Surges After $400 Million Private Placement Announcement
- Significant Financing: Immunic Inc announced a private placement of up to $400 million, including $200 million upfront, leading to a 26.43% stock price increase, reflecting strong market confidence in its future prospects.
- Strong Investor Backing: The financing was led by existing investor BVF Partners and included notable institutional backers like OrbiMed and RA Capital, indicating robust market trust and support for Immunic.
- Clear Use of Funds: The new capital is earmarked to fund the completion of the Phase 3 ENSURE trials for relapsing multiple sclerosis by late 2027, with plans to file for approval in mid-2027 if results are positive, targeting regulatory approval in 2028.
- New Project Launch: The financing will also enable Immunic to initiate a Phase 3 program for primary progressive multiple sclerosis later this year, expected to run for approximately three and a half to four years, further enhancing the company's R&D capabilities and market competitiveness.
See More
Immunic Announces Private Placement and CEO Transition
- Private Placement Announcement: Immunic has announced a private placement led by existing investor BVF Partners L.P. to raise up to $400 million, with an initial issuance of approximately 229.1 million pre-funded warrants expected to generate $200 million upfront, significantly bolstering the company's financial position for future growth.
- Equity Issuance Details: The warrants will be priced at $0.873 per share, with the offering expected to close around February 17, and the proceeds are intended to fund operations into late 2027, ensuring the company can sustain its research and commercialization efforts.
- Leadership Transition: CEO Daniel Vitt has decided to step down, prompting the board to initiate a search for a new CEO to guide the company through its next growth phase, while Vitt will assume a new senior executive role and remain on the board to facilitate a smooth transition.
- Board Restructuring: Immunic has appointed former Roche executive Simona Skerjanec as the new interim chairperson of the board, replacing Duane Nash, and plans to replace up to three directors ahead of the 2027 annual meeting to enhance governance and strategic direction.
See More
Immunic Reports FY 2025 Earnings with Positive Cash Outlook
- Earnings Highlights: Immunic reported a FY 2025 GAAP EPS of -$0.62, beating expectations by $0.05, indicating improvements in financial management despite ongoing losses.
- Cash Position: As of December 31, 2025, Immunic had approximately $15.5 million in cash and cash equivalents, providing a short-term liquidity buffer that ensures operational stability in the coming months.
- Funding Strategy: The company raised approximately $187 million in net cash from a private placement in February 2026, enabling it to fund operations into late 2027, which bolsters market confidence in its sustainability.
- Market Reaction: Following the announcement of a $400 million private placement, Immunic's stock price rose, reflecting investor optimism about the company's future, particularly in light of leadership transitions.
See More
Immunic Secures $200 Million Financing to Advance Multiple Sclerosis Research
- Successful Financing: Immunic has successfully completed an oversubscribed private placement of up to $400 million, with $200 million in initial gross proceeds, which is expected to fund its multiple sclerosis (MS) projects and facilitate the company's transition to a commercial-stage organization.
- Clinical Trial Progress: Top-line data from the ENSURE-1 and ENSURE-2 Phase 3 trials for multiple sclerosis is anticipated by the end of 2026, laying the groundwork for future drug applications and market launches, with potential regulatory approval expected in 2028.
- New Drug Application Plans: The company plans to submit a New Drug Application (NDA) in mid-2027 for vidofludimus calcium in the U.S. market, which is expected to significantly enhance its competitiveness in the projected $30 billion global multiple sclerosis market.
- Board Changes: Immunic has appointed a new interim chairperson of the board and initiated a search for a new CEO with commercial expertise to support the company's further development in the multiple sclerosis field.
See More
Immunic Secures $400 Million for MS Trials and Transition
- Successful Financing: Immunic has successfully completed an oversubscribed private placement of up to $400 million, with $200 million in upfront gross proceeds, which positions the company for a confident transition into a fully integrated commercial-stage entity, reflecting investor confidence in its multiple sclerosis (MS) treatment program.
- Clinical Trial Progress: The phase 3 ENSURE trials for Immunic's lead asset, vidofludimus calcium (IMU-838), in relapsing multiple sclerosis (RMS) are expected to yield top-line data by the end of 2026, providing critical insights for future drug applications and market entry.
- New Drug Application Plans: The company plans to submit a New Drug Application (NDA) for RMS in the U.S. by mid-2027, with a targeted regulatory approval date in 2028, which will prepare for the potential launch of vidofludimus calcium and enhance its competitive position in the global MS market projected to exceed $30 billion.
- Innovative Mechanism of Action: Vidofludimus calcium, as a first-in-class Nurr1 activator, aims to improve neuronal survival and function through direct neuroprotective effects and selective DHODH inhibition, potentially offering a best-in-class benefit-risk profile that could unlock significant commercial opportunities in MS treatment.
See More
Immunic Inc. Stock Soars on Oversubscribed Private Placement Announcement
- Funding Initiative: Immunic Inc. announced an oversubscribed private placement aimed at raising up to $400 million to accelerate its transformation into a commercial-stage company, which is expected to significantly enhance its market competitiveness.
- Equity Financing Details: The company will issue 229.08 million pre-funded warrants at $0.873 each, with expected upfront gross proceeds of $200 million, and will also issue warrants to purchase up to 229.076 million shares, potentially raising an additional $200 million.
- Clinical Trial Support: The funding is intended to support the completion of the Phase 3 ENSURE trial for relapsing multiple sclerosis, with topline data expected by the end of 2026, and plans to submit a New Drug Application in mid-2027, targeting regulatory approval in 2028.
- Leadership Changes: Immunic has made significant leadership changes by appointing Simona Skerjanec as interim Chairperson of the Board and initiating a search for a new CEO with commercial expertise, indicating a major strategic shift within the company.
See More
Immunic Inc Surges After $400 Million Private Placement Announcement
- Significant Financing: Immunic Inc announced a private placement of up to $400 million, including $200 million upfront, leading to a 26.43% stock price increase, reflecting strong market confidence in its future prospects.
- Strong Investor Backing: The financing was led by existing investor BVF Partners and included notable institutional backers like OrbiMed and RA Capital, indicating robust market trust and support for Immunic.
- Clear Use of Funds: The new capital is earmarked to fund the completion of the Phase 3 ENSURE trials for relapsing multiple sclerosis by late 2027, with plans to file for approval in mid-2027 if results are positive, targeting regulatory approval in 2028.
- New Project Launch: The financing will also enable Immunic to initiate a Phase 3 program for primary progressive multiple sclerosis later this year, expected to run for approximately three and a half to four years, further enhancing the company's R&D capabilities and market competitiveness.
See More
Immunic Announces Private Placement and CEO Transition
- Private Placement Announcement: Immunic has announced a private placement led by existing investor BVF Partners L.P. to raise up to $400 million, with an initial issuance of approximately 229.1 million pre-funded warrants expected to generate $200 million upfront, significantly bolstering the company's financial position for future growth.
- Equity Issuance Details: The warrants will be priced at $0.873 per share, with the offering expected to close around February 17, and the proceeds are intended to fund operations into late 2027, ensuring the company can sustain its research and commercialization efforts.
- Leadership Transition: CEO Daniel Vitt has decided to step down, prompting the board to initiate a search for a new CEO to guide the company through its next growth phase, while Vitt will assume a new senior executive role and remain on the board to facilitate a smooth transition.
- Board Restructuring: Immunic has appointed former Roche executive Simona Skerjanec as the new interim chairperson of the board, replacing Duane Nash, and plans to replace up to three directors ahead of the 2027 annual meeting to enhance governance and strategic direction.
See More
